Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Metagenomi (MGX) EBT (2023 - 2025)

Metagenomi (MGX) has disclosed EBT for 3 consecutive years, with -$22.5 million as the latest value for Q4 2025.

  • On a quarterly basis, EBT rose 8.58% to -$22.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$87.9 million, a 5.21% decrease, with the full-year FY2025 number at -$87.9 million, down 5.21% from a year prior.
  • EBT was -$22.5 million for Q4 2025 at Metagenomi, down from -$20.6 million in the prior quarter.
  • In the past five years, EBT ranged from a high of -$11.1 million in Q2 2023 to a low of -$25.1 million in Q1 2024.
  • A 3-year average of -$19.3 million and a median of -$20.2 million in 2025 define the central range for EBT.
  • Peak YoY movement for EBT: plummeted 80.45% in 2024, then rose 8.58% in 2025.
  • Metagenomi's EBT stood at -$16.6 million in 2023, then plummeted by 48.52% to -$24.6 million in 2024, then increased by 8.58% to -$22.5 million in 2025.
  • Per Business Quant, the three most recent readings for MGX's EBT are -$22.5 million (Q4 2025), -$20.6 million (Q3 2025), and -$19.9 million (Q2 2025).